13h
Clinical Trials Arena on MSNPalisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trialThe trial’s primary objective is to assess PALI-2108’s tolerability, pharmacokinetics and safety in healthy volunteers.
In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results